SyntheticMR sells first software to Bern

Accelerators subsidiary SyntheticMR has together with distributor Sectra secured the first order for the software SyMRI Suite from the Institute of Forensic Medicine at the University of Bern. The software will enhance quality in conjunction with virtual autopsies.

“SyMRI Suite provides us with increased safety and higher efficiency in our work,” says Professor Michael Thali, head of the Institute of Forensic Medicine at the University of Bern.

The SyMRI Suite was rolled out at the beginning of 2010 and the University of Bern is the first of a handful of pilot customers that have chosen to purchase the software.

The software for synthetic magnetic resonance (MR) helps hospital personnel to drastically reduce the time required per patient for MR examinations, thus increasing the availability of the MR equipment. In addition, tissue can be quantified, identified and its volume determined.

“The agreement with the Institute of Forensic Medicine in Bern is not only a confirmation of the value that SyMRI Suite has as a diagnostic support product but also the beginning of a interesting cooperation with a world leading institute within pathology, says Marcel Warntjes, CEO at SyntheticMR.

“We are happy for SyntheticMR’s first sales.  That the first order comes from Bern, Switzerland shows that there is an international interest for the software and the products broad field of use”, says Andreas Bunge, CEO at Accelerator.

MR examinations have increased steadily since the 1980s. MR technology is effective in cases involving tumors, aneurysms, examining the condition of organs as the heart, liver, kidneys and brain and in different soft tissue.

Accelerator Nordic AB holds 64 percent of the stocks in Synthetic MR.

For further information, please contact:

Andreas Bunge, CEO at Accelerator Nordic AB, phone +46 70 8 24 25 25

SyntheticMR AB develops analytical and imaging methods for synthetic magnetic resonance (MR). Synthetic MR helps hospital personnel to drastically reduce the time required for MR imaging, thus increasing the availability of the MR equipment. Other advantages of synthetic MR are improved performance from current image analysis equipment and the possibility to provide more precise MR evaluations. For more information, please visit www.syntheticmr.se.

Accelerator Nordic AB is a group of developing companies based on Scandinavian Life Science. The company holds an active majority position in a number of companies providing Pharmaceutical and Medical technology products. The Accelerator Group is addressing therapeutics and imaging in large growth markets such as oncology, cardiology and drug delivery for orthopedic and dental implants. Products are in clinical phase II and initial commercialization phase. The business model is centred on partnering or out-licensing. Accelerator Nordic is publicly traded on the Aktietorget exchange in Stockholm, Sweden. For more information, please visit, www.acceleratorab.se